SG11201503977PA - Azaindole derivatives as jak3 inhibitors - Google Patents

Azaindole derivatives as jak3 inhibitors

Info

Publication number
SG11201503977PA
SG11201503977PA SG11201503977PA SG11201503977PA SG11201503977PA SG 11201503977P A SG11201503977P A SG 11201503977PA SG 11201503977P A SG11201503977P A SG 11201503977PA SG 11201503977P A SG11201503977P A SG 11201503977PA SG 11201503977P A SG11201503977P A SG 11201503977PA
Authority
SG
Singapore
Prior art keywords
azaindole derivatives
jak3 inhibitors
jak3
inhibitors
azaindole
Prior art date
Application number
SG11201503977PA
Inventor
David Michael Goldstein
Kenneth Albert Brameld
Tim Owens
Original Assignee
Principia Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Principia Biopharma Inc filed Critical Principia Biopharma Inc
Publication of SG11201503977PA publication Critical patent/SG11201503977PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG11201503977PA 2012-11-20 2013-11-19 Azaindole derivatives as jak3 inhibitors SG11201503977PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261728539P 2012-11-20 2012-11-20
PCT/US2013/070834 WO2014081732A1 (en) 2012-11-20 2013-11-19 Azaindole derivatives as jak3 inhibitors

Publications (1)

Publication Number Publication Date
SG11201503977PA true SG11201503977PA (en) 2015-06-29

Family

ID=49674421

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201503977PA SG11201503977PA (en) 2012-11-20 2013-11-19 Azaindole derivatives as jak3 inhibitors

Country Status (8)

Country Link
US (1) US9676778B2 (en)
EP (1) EP2922538B1 (en)
JP (1) JP2016500076A (en)
KR (1) KR20150085068A (en)
CN (1) CN104853754A (en)
AU (1) AU2013348116A1 (en)
SG (1) SG11201503977PA (en)
WO (1) WO2014081732A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2922538B1 (en) * 2012-11-20 2016-10-19 Principia Biopharma Inc. Azaindole derivatives as jak3 inhibitors
US9206188B2 (en) * 2013-04-18 2015-12-08 Arrien Pharmaceuticals Llc Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
WO2015013581A1 (en) 2013-07-26 2015-01-29 Update Pharma Inc. Combinatorial methods to improve the therapeutic benefit of bisantrene
PT3318565T (en) 2013-12-05 2021-05-28 Pfizer Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides
CN105777756B (en) * 2014-07-02 2019-03-01 广东东阳光药业有限公司 Heteroaryl compound and its application in drug
AU2016209046A1 (en) * 2015-01-23 2017-07-20 Aclaris Therapeutics, Inc. Heterocyclic ITK inhibitors for treating inflammation and cancer
CN109422751B (en) * 2017-09-03 2022-04-22 上海美志医药科技有限公司 Compound with activity of degrading tyrosine protein kinase JAK3
US20210292333A1 (en) 2018-06-15 2021-09-23 Cadila Healthcare Limited Condensed azaheteroaryl compounds having antibacterial activity against tuberculosis bacteria
WO2023248010A2 (en) 2022-06-23 2023-12-28 Synovo Gmbh Targeted modulators of jak3 for treatment of inflammatory and autoimmune diseases
CN116396299B (en) * 2023-06-06 2023-08-29 和鼎（南京）医药技术有限公司 Method for preparing Wu Pa tenib intermediate

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
PL2247592T3 (en) 2008-02-25 2012-01-31 Hoffmann La Roche Pyrrolopyrazine kinase inhibitors
TW201041888A (en) 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
EP2922538B1 (en) * 2012-11-20 2016-10-19 Principia Biopharma Inc. Azaindole derivatives as jak3 inhibitors

Also Published As

Publication number Publication date
CN104853754A (en) 2015-08-19
US20150291600A1 (en) 2015-10-15
EP2922538B1 (en) 2016-10-19
EP2922538A1 (en) 2015-09-30
AU2013348116A1 (en) 2015-06-11
KR20150085068A (en) 2015-07-22
US9676778B2 (en) 2017-06-13
WO2014081732A1 (en) 2014-05-30
JP2016500076A (en) 2016-01-07

Similar Documents

Publication Publication Date Title
HRP20180450T1 (en) Heterobicyclic compounds as beta-lactamase inhibitors
HK1226394A1 (en) 7 azaindole derivatives
HK1212984A1 (en) Imidazopyridine compounds
IL234183A (en) Pyrazolotriazine derivatives as selective cyclin-dependent kinase inhibitors
HK1211027A1 (en) Pyrrolotriazinone derivatives as pi3k inhibitors pi3k
IL221823A (en) Piperidin-4-yl-azetidine derivatives as jak1 inhibitors
HK1210771A1 (en) Azaindole derivatives which act as pi3k inhibitors
EP2863914A4 (en) Pyrazolyl derivatives as syk inhibitors
HK1208453A1 (en) Substituted pyridopyrimidine compounds and their use as flt3 inhibitors flt3
SG11201503977PA (en) Azaindole derivatives as jak3 inhibitors
ZA201407695B (en) Triazolo compounds as pde 10 inhibitors
ZA201409497B (en) Tetrahydroquinazolinone derivatives as parp inhibitors
HK1212331A1 (en) 4-carboxamido-isoindolinone derivatives as selective parp-1 inhibitors parp-1 4--
HK1199024A1 (en) Novel morpholinyl derivatives useful as mogat-2 inhibitors mogat-2
EP2922543A4 (en) Substituted pyridone derivatives as pde10 inhibitors
HK1208029A1 (en) Imidazopyridine derivatives
HK1214244A1 (en) Imidazopyridine derivatives